Curated News:

Medical Meetings

Add to Favorites Subscribe Share
fbshare-Medical Meetings

Showing results

3140 of 3636
ecigarette.jpg
  • Embargo expired:
    20-May-2019 3:15 PM EDT

Article ID: 712564

E-Cigarettes Appear to Reduce Body’s Ability to Fight Flu

American Thoracic Society (ATS)

E-cigarettes may diminish the body’s ability to fight viruses, specifically those that cause the flu, according to research presented at ATS 2019.

Released:
13-May-2019 8:00 AM EDT
opiateuseinICU.jpg
  • Embargo expired:
    20-May-2019 3:15 PM EDT

Article ID: 712573

Opiate Use in ICU Does Not Appear to Increase Opiate Prescription a Year After Discharge

American Thoracic Society (ATS)

Patients given opioids in the intensive care unit do not appear to be at higher risk of receiving opioid prescriptions once they leave the hospital, according to research presented at ATS 2019.

Released:
13-May-2019 8:00 AM EDT
ICUPhoto.jpg
  • Embargo expired:
    20-May-2019 3:15 PM EDT

Article ID: 712974

Do Family Members Belong in ICU During Procedures with Loved Ones? Study Finds Clinicians Mixed About Practice

Intermountain Healthcare

Do family members of loved ones who are critically ill and being treated in an intensive care unit at a hospital belong there when clinicians are performing bedside procedures? New study finds many critical care clinicians have conflicting feelings about the practice.

Released:
16-May-2019 8:35 AM EDT
GettyImages-858485076.jpg
  • Embargo expired:
    20-May-2019 3:15 PM EDT

Article ID: 713139

New Computer-Based Predictive Tool More Accurately Forecasts Outcomes for Respiratory Patients

Intermountain Healthcare

Are electronic health records and computer calculations a better, more accurate way to predict clinical outcomes for patients with chronic obstructive pulmonary disease? According to the results of a new study by researchers at Intermountain Healthcare in Salt Lake City, the answer is yes.

Released:
20-May-2019 9:00 AM EDT
ISPOR_KyleKlein_KK4_7046.jpg

Article ID: 713204

The Dawn of Disruption in Healthcare

ISPOR—The Professional Society for Health Economics and Outcomes Research

ISPOR, the professional society for health economics and outcomes research (HEOR), opened its ISPOR 2019 annual conference this morning with a keynote and first plenary, “The Dawn of Disruption in the Health Sector: Will Innovative Technologies Require Innovative Thinking?”

Released:
20-May-2019 3:05 PM EDT
asthma_lungcheck.jpg
  • Embargo expired:
    20-May-2019 10:45 AM EDT

Article ID: 712558

New Investigational Therapy Shows Promise for Asthma Patients in Phase 2 Trial

American Thoracic Society (ATS)

In a Phase 2 trial, RTB101, which belongs to a class of drugs known as TORC1 inhibitors, was observed to be well tolerated and to reduce the incidence of respiratory tract infections in adults age 65 and older when given once daily for 16 weeks during winter cold and flu season

Released:
13-May-2019 8:00 AM EDT
miningcoal.jpg
  • Embargo expired:
    20-May-2019 10:15 AM EDT

Article ID: 712477

Younger Generations of Miners More Likely to Die From Black Lung Disease Than Older Generations

American Thoracic Society (ATS)

Black lung disease and other non-malignant respiratory diseases appear to account for a greater proportion of deaths in younger generations of coal miners than in older generations of miners, according to research presented at ATS 2019.

Released:
13-May-2019 8:00 AM EDT
coalminers.jpg
  • Embargo expired:
    20-May-2019 10:15 AM EDT

Article ID: 712485

Worst Form of Black Lung Disease Is on the Rise but the Cause Remains Unknown

American Thoracic Society (ATS)

Progressive massive fibrosis (PMF), the worst form of black lung disease, is rising among coal miners, but the reasons for this trend remain unclear, according to research presented at ATS 2019.

Released:
13-May-2019 8:00 AM EDT
ats-logo.gif
  • Embargo expired:
    20-May-2019 10:15 AM EDT

Article ID: 712490

Long-Term Use of Benralizumab Appears Safe, Effective for Severe Asthma

American Thoracic Society (ATS)

Patients with severe eosinophilic asthma, who participated in three different Phase 3 trials of benralizumab (brand name Fasenra) and then enrolled in a long-term trial of the drug’s efficacy and safety, continued to experience fewer exacerbations and improved pulmonary function and quality of life

Released:
13-May-2019 8:00 AM EDT
asthmapatient.jpg
  • Embargo expired:
    20-May-2019 10:15 AM EDT

Article ID: 712500

Enzyme May Represent New Target for Treating Asthma

American Thoracic Society (ATS)

An enzyme called diacylglycerol kinase zeta (DGKζ) appears to play an important role in suppressing runaway inflammation in asthma and may represent a novel therapeutic target,

Released:
13-May-2019 8:00 AM EDT

Showing results

3140 of 3636

Chat now!